Abstract
Consecutive non-replicate clinical isolates (n=191) of carbapenem non-susceptible Enterobacteriaceae were collected from 21 hospital laboratories across Italy from November 2013 to April 2014 as part of the European Survey on Carbapenemase-producing Enterobacteriaceae (EuSCAPE) project. Klebsiella pneumonia carbapenemase-producing K. pneumoniae (KPC-KP) represented 178 (93%) isolates with 76 (43%) respectively resistant to colistin, a key drug for treating carbapenamase-producing Enterobacteriaceae. KPC-KP colistin-resistant isolates were detected in all participating laboratories. This underscores a concerning evolution of colistin resistance in a setting of high KPC-KP endemicity.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Bacterial Agents / pharmacology*
-
Anti-Bacterial Agents / therapeutic use
-
Bacterial Proteins / genetics
-
Bacterial Proteins / metabolism*
-
Carbapenems / pharmacology*
-
Colistin / pharmacology*
-
Colistin / therapeutic use
-
Drug Resistance, Multiple, Bacterial
-
Endemic Diseases
-
Health Surveys
-
Humans
-
Italy / epidemiology
-
Klebsiella Infections / drug therapy
-
Klebsiella Infections / epidemiology
-
Klebsiella pneumoniae / drug effects*
-
Klebsiella pneumoniae / enzymology*
-
Klebsiella pneumoniae / genetics
-
Klebsiella pneumoniae / isolation & purification
-
Laboratories, Hospital
-
Microbial Sensitivity Tests
-
Polymerase Chain Reaction
-
Sentinel Surveillance
-
beta-Lactamases / genetics
-
beta-Lactamases / metabolism*
Substances
-
Anti-Bacterial Agents
-
Bacterial Proteins
-
Carbapenems
-
beta-Lactamases
-
carbapenemase
-
Colistin